CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for tough prostate cancer falls short in early trial
Disease control TerminatedThis study tested a combination of two drugs, apalutamide and abiraterone acetate, plus prednisone, in men with castration-resistant prostate cancer that had spread. The goal was to see if the combo could slow cancer growth. Only 7 people enrolled before the study was stopped ear…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
Prostate cancer drug study halted early – what researchers learned
Disease control TerminatedThis study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to bone. The goal was to see if the drug could slow the cancer and to study changes in blood and bone marrow. The study was stopped early, so results are limited.
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo aims to outsmart drug resistance in advanced prostate cancer
Disease control TerminatedThis early-phase trial tested a combination of two drugs—decitabine/cedazuridine and enzalutamide—in 8 men with metastatic castration-resistant prostate cancer that had stopped responding to standard treatment. The goal was to find a safe dose and see if the combination could rev…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Promising combo for Hard-to-Treat prostate cancer hits roadblock
Disease control TerminatedThis study looked at adding a drug called ribociclib to standard hormone therapy (enzalutamide) for men with advanced prostate cancer that had spread and stopped responding to hormone treatment. The goal was to find a safe dose and see if the combination could lower PSA levels. T…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Radioactive treatment aims to ease bone pain in prostate cancer patients
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that has spread to the bones. Only one person took part before the study was stopped early. The goal was to measure pain relief over several weeks.
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC